NOT KNOWN DETAILS ABOUT BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES

In Phase A, members will obtain distinct doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Supplemental members are going to be enrolled for the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 might be presented as "include-on" therapy. In Phase C, individual